JP Morgan Chase
ALXO icon

JP Morgan Chase’s ALX Oncology ALXO Stock Holding History

JP Morgan Chase’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$189 Hold
99
– – ﹤0.01% 7256
2025
Q4 		$112 Sell
99
-61,800
-100% -$93.6K ﹤0.01% 7201
2025
Q3 		$113K Sell
61,899
-26,453
-30% -$22.9K ﹤0.01% 5832
2025
Q2 		$36.7K Sell
88,352
-269,605
-75% -$136K ﹤0.01% 6023
2025
Q1 		$223K Buy
357,957
+121,911
+52% +$146K ﹤0.01% 5198
2024
Q4 		$394K Buy
236,046
+195,112
+477% +$300K ﹤0.01% 5160
2024
Q3 		$74.5K Buy
40,934
+509
+1% +$1.89K ﹤0.01% 5826
2024
Q2 		$244K Sell
40,425
-1,472
-4% -$18.1K ﹤0.01% 5062
2024
Q1 		$467K Sell
41,897
-5,686
-12% -$79.9K ﹤0.01% 4840
2023
Q4 		$709K Buy
47,583
+25,848
+119% +$245K ﹤0.01% 4557
2023
Q3 		$104K Buy
21,735
+3,179
+17% +$17.2K ﹤0.01% 5449
2023
Q2 		$139K Buy
18,556
+749
+4% +$4.9K ﹤0.01% 5293
2023
Q1 		$81K Buy
17,807
+4,391
+33% +$33.3K ﹤0.01% 5517
2022
Q4 		$151K Sell
13,416
-1,165
-8% -$13.1K ﹤0.01% 5176
2022
Q3 		$140K Buy
14,581
+1,153
+9% +$13.4K ﹤0.01% 5125
2022
Q2 		$109K Sell
13,428
-5,809
-30% -$63.3K ﹤0.01% 5362
2022
Q1 		$326K Buy
19,237
+3,417
+22% +$58.3K ﹤0.01% 4941
2021
Q4 		$340K Buy
15,820
+792
+5% +$34.2K ﹤0.01% 5054
2021
Q3 		$1.11M Buy
15,028
+2,683
+22% +$179K ﹤0.01% 4234
2021
Q2 		$675K Buy
12,345
+2,413
+24% +$144K ﹤0.01% 4520
2021
Q1 		$732K Buy
9,932
+4,838
+95% +$381K ﹤0.01% 4439
2020
Q4 		$439K Buy
5,094
+1,526
+43% +$91.8K ﹤0.01% 4441
2020
Q3 		$137K Buy
+3,568
New +$140K ﹤0.01% 4560

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

JP Morgan Chase's ALXO Position: Q1 2026 in Review

JP Morgan Chase held its ALX Oncology (ALXO) position steady in Q1 2026 at 99 shares worth $189. The position accounts for ﹤0.01% of the portfolio, ranked #7256.

JP Morgan Chase first reported a position in ALXO in Q3 2020 and has held it in 23 quarters since. The position peaked at $1.11M in Q3 2021. 69 funds tracked by Wall St. Rank hold ALXO as of Q1 2026.

  • JP Morgan Chase held 99 shares of ALX Oncology worth $189 as of Q1 2026.
  • JP Morgan Chase left its ALX Oncology share count unchanged in Q1 2026.
  • ALX Oncology made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7256 holding.
  • JP Morgan Chase first reported a position in ALX Oncology in Q3 2020 and has held it in 23 quarters since.
  • JP Morgan Chase's ALX Oncology position peaked at $1.11M in Q3 2021.
  • 69 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.